Cargando…

Anti-TGF-β Antibody, 1D11, Ameliorates Glomerular Fibrosis in Mouse Models after the Onset of Proteinuria

Fibrosis is a final common pathway leading to loss of kidney function, in which the fibrogenic cytokine, transforming growth factor β (TGF-β), plays a central role. While previous studies showed that TGF-β antagonism by various means prevents fibrosis in mouse models, clinical approaches based on th...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Xiaoyan, Schnaper, H. William, Matsusaka, Taiji, Pastan, Ira, Ledbetter, Steve, Hayashida, Tomoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4871338/
https://www.ncbi.nlm.nih.gov/pubmed/27187580
http://dx.doi.org/10.1371/journal.pone.0155534
_version_ 1782432568601214976
author Liang, Xiaoyan
Schnaper, H. William
Matsusaka, Taiji
Pastan, Ira
Ledbetter, Steve
Hayashida, Tomoko
author_facet Liang, Xiaoyan
Schnaper, H. William
Matsusaka, Taiji
Pastan, Ira
Ledbetter, Steve
Hayashida, Tomoko
author_sort Liang, Xiaoyan
collection PubMed
description Fibrosis is a final common pathway leading to loss of kidney function, in which the fibrogenic cytokine, transforming growth factor β (TGF-β), plays a central role. While previous studies showed that TGF-β antagonism by various means prevents fibrosis in mouse models, clinical approaches based on these findings remain elusive. 1D11 is a neutralizing antibody to all three isoforms of TGF-β. In both adriamycin (ADR)-induced nephropathy and NEP25 podocyte ablation nephropathy, thrice-weekly intraperitoneal administration of 1D11 from the day of disease induction until the mice were sacrificed (day 14 for ADR and day 28 for NEP25), significantly reduced glomerular COL1A2 mRNA accumulation and histological changes. Consistent with our previous findings, proteinuria remained overt in the mice treated with 1D11, suggesting distinct mechanisms for proteinuria and fibrogenesis. Podocyte numbers determined by WT1 staining were significantly reduced in NEP25-model glomeruli as expected, while WT1-positive cells were preserved in mice receiving 1D11. Even when 1D11 was administered after the onset of proteinuria on day 3, 1D11 preserved WT1-positive cell numbers in glomeruli and significantly reduced glomerular scar score (2.5 ± 0.2 [control IgG] vs. 1.8 ± 0.2 [1D11], P < 0.05) and glomerular COL1A2 mRNA expression (19.3 ± 4.4 [control IgG] vs. 8.4 ± 2.4 [1D11] fold increase over the healthy control, P < 0.05). Transmission electron microscopy revealed loss of podocytes and denuded glomerular basement membrane in NEP25 mice with disease, whereas podocytes remained attached to the basement membrane, though effaced and swollen, in those receiving 1D11 from day 3. Together, these data suggest that TGF-β neutralization by 1D11 prevents glomerular fibrosis even when started after the onset of proteinuria. While overt proteinuria and podocyte effacement persist, 1D11 prevents total podocytes detachment, which might be a key event activating fibrogenic events in glomeruli.
format Online
Article
Text
id pubmed-4871338
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-48713382016-05-31 Anti-TGF-β Antibody, 1D11, Ameliorates Glomerular Fibrosis in Mouse Models after the Onset of Proteinuria Liang, Xiaoyan Schnaper, H. William Matsusaka, Taiji Pastan, Ira Ledbetter, Steve Hayashida, Tomoko PLoS One Research Article Fibrosis is a final common pathway leading to loss of kidney function, in which the fibrogenic cytokine, transforming growth factor β (TGF-β), plays a central role. While previous studies showed that TGF-β antagonism by various means prevents fibrosis in mouse models, clinical approaches based on these findings remain elusive. 1D11 is a neutralizing antibody to all three isoforms of TGF-β. In both adriamycin (ADR)-induced nephropathy and NEP25 podocyte ablation nephropathy, thrice-weekly intraperitoneal administration of 1D11 from the day of disease induction until the mice were sacrificed (day 14 for ADR and day 28 for NEP25), significantly reduced glomerular COL1A2 mRNA accumulation and histological changes. Consistent with our previous findings, proteinuria remained overt in the mice treated with 1D11, suggesting distinct mechanisms for proteinuria and fibrogenesis. Podocyte numbers determined by WT1 staining were significantly reduced in NEP25-model glomeruli as expected, while WT1-positive cells were preserved in mice receiving 1D11. Even when 1D11 was administered after the onset of proteinuria on day 3, 1D11 preserved WT1-positive cell numbers in glomeruli and significantly reduced glomerular scar score (2.5 ± 0.2 [control IgG] vs. 1.8 ± 0.2 [1D11], P < 0.05) and glomerular COL1A2 mRNA expression (19.3 ± 4.4 [control IgG] vs. 8.4 ± 2.4 [1D11] fold increase over the healthy control, P < 0.05). Transmission electron microscopy revealed loss of podocytes and denuded glomerular basement membrane in NEP25 mice with disease, whereas podocytes remained attached to the basement membrane, though effaced and swollen, in those receiving 1D11 from day 3. Together, these data suggest that TGF-β neutralization by 1D11 prevents glomerular fibrosis even when started after the onset of proteinuria. While overt proteinuria and podocyte effacement persist, 1D11 prevents total podocytes detachment, which might be a key event activating fibrogenic events in glomeruli. Public Library of Science 2016-05-17 /pmc/articles/PMC4871338/ /pubmed/27187580 http://dx.doi.org/10.1371/journal.pone.0155534 Text en © 2016 Liang et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Liang, Xiaoyan
Schnaper, H. William
Matsusaka, Taiji
Pastan, Ira
Ledbetter, Steve
Hayashida, Tomoko
Anti-TGF-β Antibody, 1D11, Ameliorates Glomerular Fibrosis in Mouse Models after the Onset of Proteinuria
title Anti-TGF-β Antibody, 1D11, Ameliorates Glomerular Fibrosis in Mouse Models after the Onset of Proteinuria
title_full Anti-TGF-β Antibody, 1D11, Ameliorates Glomerular Fibrosis in Mouse Models after the Onset of Proteinuria
title_fullStr Anti-TGF-β Antibody, 1D11, Ameliorates Glomerular Fibrosis in Mouse Models after the Onset of Proteinuria
title_full_unstemmed Anti-TGF-β Antibody, 1D11, Ameliorates Glomerular Fibrosis in Mouse Models after the Onset of Proteinuria
title_short Anti-TGF-β Antibody, 1D11, Ameliorates Glomerular Fibrosis in Mouse Models after the Onset of Proteinuria
title_sort anti-tgf-β antibody, 1d11, ameliorates glomerular fibrosis in mouse models after the onset of proteinuria
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4871338/
https://www.ncbi.nlm.nih.gov/pubmed/27187580
http://dx.doi.org/10.1371/journal.pone.0155534
work_keys_str_mv AT liangxiaoyan antitgfbantibody1d11amelioratesglomerularfibrosisinmousemodelsaftertheonsetofproteinuria
AT schnaperhwilliam antitgfbantibody1d11amelioratesglomerularfibrosisinmousemodelsaftertheonsetofproteinuria
AT matsusakataiji antitgfbantibody1d11amelioratesglomerularfibrosisinmousemodelsaftertheonsetofproteinuria
AT pastanira antitgfbantibody1d11amelioratesglomerularfibrosisinmousemodelsaftertheonsetofproteinuria
AT ledbettersteve antitgfbantibody1d11amelioratesglomerularfibrosisinmousemodelsaftertheonsetofproteinuria
AT hayashidatomoko antitgfbantibody1d11amelioratesglomerularfibrosisinmousemodelsaftertheonsetofproteinuria